Purespring Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$106M
- Investors
-
6
Purespring Therapeutics General Information
Description
Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. The company offers a podocyte-focused gene therapy platform that directs vectors to glomerular structures, aims to maintain kidney filtration function, concentrates on modulating complement signalling in the glomeruli through its lead program for IgA nephropathy, and advances additional candidates for monogenic podocyte disorders such as NPHS2 nephropathy and glomerular basement membrane deficiencies, enabling nephrologists healthcare providers researchers and patients to access disease-modifying therapeutic approaches aimed at delaying or preventing progression to end-stage renal disease dialysis or kidney transplant.
Contact Information
Website
www.purespringtx.comCorporate Office
- 8 Bloomsbury Street
- London WC1B 3SR
- England, United Kingdom
Corporate Office
- 8 Bloomsbury Street
- London WC1B 3SR
- England, United Kingdom
Purespring Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 08-Oct-2024 | $106M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | 19-Nov-2020 | Completed | Pre-Clinical Trials | |||
| 1. Spin-Off | 01-Apr-2020 | Completed | Startup |
Purespring Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A | 18,500,000 | $0.000013 | $1.32 | $1.32 | 1x | $1.32 | 13.1% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Purespring Therapeutics Patents
Purespring Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202511557-D0 | Gene system | Inactive | 16-Jul-2025 | ||
| GB-202511174-D0 | Methods | Pending | 10-Jul-2025 | ||
| GB-202510228-D0 | Gene system | Pending | 26-Jun-2025 | ||
| GB-202508472-D0 | Gene system | Pending | 30-May-2025 | ||
| GB-202508471-D0 | Vectors | Pending | 30-May-2025 | C12N15/86 |
Purespring Therapeutics Signals
Purespring Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Gilde Healthcare | PE/Buyout | Minority | ||
| Sofinnova Partners | Venture Capital | Minority | ||
| Syncona | Venture Capital | Minority |
Purespring Therapeutics FAQs
-
When was Purespring Therapeutics founded?
Purespring Therapeutics was founded in 2020.
-
Where is Purespring Therapeutics headquartered?
Purespring Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Purespring Therapeutics?
Purespring Therapeutics has 50 total employees.
-
What industry is Purespring Therapeutics in?
Purespring Therapeutics’s primary industry is Drug Discovery.
-
Is Purespring Therapeutics a private or public company?
Purespring Therapeutics is a Private company.
-
What is the current valuation of Purespring Therapeutics?
The current valuation of Purespring Therapeutics is .
-
What is Purespring Therapeutics’s current revenue?
The current revenue for Purespring Therapeutics is .
-
How much funding has Purespring Therapeutics raised over time?
Purespring Therapeutics has raised $165M.
-
Who are Purespring Therapeutics’s investors?
British Business Bank, Forbion, Gilde Healthcare, Sofinnova Partners, and Syncona are 5 of 6 investors who have invested in Purespring Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process